- Home
- SISI vs REVB Comparison
SISI vs REVB Comparison
Compare SISI & REVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SISI
- REVB
- Stock Information
- Founded
- SISI 1997
- REVB 2020
- Country
- SISI China
- REVB United States
- Employees
- SISI N/A
- REVB N/A
- Industry
- SISI Medicinal Chemicals and Botanical Products
- REVB Biotechnology: Pharmaceutical Preparations
- Sector
- SISI Health Care
- REVB Health Care
- Exchange
- SISI Nasdaq
- REVB Nasdaq
- Market Cap
- SISI 5.9M
- REVB 5.4M
- IPO Year
- SISI 2016
- REVB N/A
- Fundamental
- Price
- SISI $1.65
- REVB $0.34
- Analyst Decision
- SISI
- REVB
- Analyst Count
- SISI 0
- REVB 0
- Target Price
- SISI N/A
- REVB N/A
- AVG Volume (30 Days)
- SISI 613.8K
- REVB 6.8M
- Earning Date
- SISI 02-06-2025
- REVB 11-08-2024
- Dividend Yield
- SISI N/A
- REVB N/A
- EPS Growth
- SISI N/A
- REVB N/A
- EPS
- SISI N/A
- REVB N/A
- Revenue
- SISI $10,330,284.00
- REVB N/A
- Revenue This Year
- SISI N/A
- REVB N/A
- Revenue Next Year
- SISI N/A
- REVB N/A
- P/E Ratio
- SISI N/A
- REVB N/A
- Revenue Growth
- SISI 370.34
- REVB N/A
- 52 Week Low
- SISI $1.63
- REVB $0.28
- 52 Week High
- SISI $117.65
- REVB $25.26
- Technical
- Relative Strength Index (RSI)
- SISI 40.35
- REVB 35.89
- Support Level
- SISI $1.66
- REVB $0.34
- Resistance Level
- SISI $1.89
- REVB $0.53
- Average True Range (ATR)
- SISI 0.34
- REVB 0.12
- MACD
- SISI -0.03
- REVB -0.01
- Stochastic Oscillator
- SISI 1.18
- REVB 0.62
About SISI Shineco Inc.
Shineco Inc aims to care for a healthy life and improve the quality of life by providing safe, efficient, and high-quality health products and services to society. The company has researched and developed various vitro diagnostic reagents and related medical devices to date, and it also produces and sells healthy and nutritious food.
About REVB Revelation Biosciences Inc.
Revelation Biosciences Inc is a clinical-stage life sciences company focused on the development of therapies for the prevention and treatment of disease using trained immunity. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).